ANN ARBOR, Mich., March 24, 2011 /PRNewswire/ — Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that Ashley I. Bush, M.D., Ph.D., has joined the Company’s Scientific Advisory Board.

Dr. Bush is a National Health and Medical Research Council Australia Fellow and Head of the Oxidation Disorders Laboratory for the Mental Health Research Institute, University of Melbourne. He has been published in the journal, Science, and has been featured in a front page article in The Wall Street Journal. Dr. Bush theorizes that the buildup of insoluble protein, called amyloid, within the brain in Alzheimer’s disease is caused by an imbalance in the import and export of the vital trace metals, such as copper, zinc and iron.

“Given my research in the area, I believe Adeona’s product candidate for the dietary management of Alzheimer’s disease, reaZin™, shows significant potential,” said Ashley I. Bush, M.D., Ph.D. “I look forward to advising Adeona as they move their promising zinc-based product candidate through development for the treatment of Alzheimer’s disease.”

“We are very pleased to welcome Dr. Bush to our Scientific Advisory Board. He is a respected expert in the research and development of new treatments for Alzheimer’s disease based on the regulation of particular biometals,” stated James S. Kuo, M.D., M.B.A., Adeona’s Chairman and CEO. “We look forward to Dr. Bush’s valuable advisory role in advancing our development and product commercialization plans in Alzheimer’s.”

About Ashley I. Bush, M.D., Ph.D.

Ashley I. Bush, M.D., Ph.D., is a National Health and Medical Research Council Australia Fellow and Head of the Oxidation Disorders Laboratory for the Mental Health Research Institute, University of Melbourne. He has also served as the Director of the Laboratory for Oxidation Biology, Massachusetts General Hospital and Associate Professor of Psychiatry at Harvard Medical School. A board certified psychiatrist, Dr. Bush earned a Ph.D. in neuroscience at the University of Melbourne, and did postdoctoral research at Harvard. He is also a co-founding scientist of Prana Biotechnology, Ltd. Dr. Bush is the recipient of several awards including the Potamkin Prize for Alzheimer’s disease research from the American Academy of Neurology, the Paul B. Beeson Award in Aging from The National Institute on Aging and the American Federation for Aging Research and the Senator Mark A. Hatfield Award for Clinical Research from the Alzheimer’s Association, and has authored over 170 publications with over 14,000 citations.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company’s strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer’s disease, and drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis. For more information, please visit Adeona’s website at www.adeonapharma.com.

This release includes forward-looking statements on Adeona’s current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the potential of reaZin™. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona’s forward-looking statements include, among others, a failure of our clinical trials to be completed on time or to achieve desired result and the failure of reaZin to be successfully commercialized. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

SOURCE Adeona Pharmaceuticals, Inc.